Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

Journal Articles

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2008) 112 (11): 653.

https://doi.org/10.1182/blood.V112.11.653.653

Published: 2008

Journal Articles

Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study

Thomas M. Moehler, Anatoli Golenkov, MD, Heinz Ludwig, Martin H Kropff, Nuriet K Khuageva, E. A Osmanov, I. Broen, MD, H. Goldschmidt

Blood (2008) 112 (11): 5195.

https://doi.org/10.1182/blood.V112.11.5195.5195

Published: 2008

Journal Articles

Gene Expression Profiles for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients Included in a Prospective, Multicenter, Phase 3 Trial.

A. Broyl, J. Peeters, D. Hose, Y. de Knegt, B. Beverloo, H. Lokhorst, H. Goldschmidt, M. van Duin, P. Sonneveld

Blood (2008) 112 (11): 1683.

https://doi.org/10.1182/blood.V112.11.1683.1683

Published: 2008

Journal Articles

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Gareth J. Morgan, MD, PhD, David C. Johnson, BSc, John Crowley, PhD, John Shaughnessy, Jr., PhD, Pieter Sonneveld, MD, Brian Durie, MD, Christine Ramos, PhD, Brian G. Van Ness, PhD, Bart Barlogie, MD, Antje Hoering, PhD, Jeff Haessler, PhD, Dalsu Baris, MD, PhD, Michael Katz, BS, Vincent S. Rajkumar, MD, H. Goldschmidt, MD

Blood (2006) 108 (11): 246.

https://doi.org/10.1182/blood.V108.11.246.246

Published: 2006

Journal Articles

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Ralf Angermund, MD, W. Knauf, MD, M. Freund, MD, M. Nowrousian, MD, H. Einsele, MD, H. Goldschmidt, MD, W. Berdel, MD, W. Poenisch, MD, C. Straka, MD, L. Kellermann, H. Pliskat, PhD

Blood (2006) 108 (11): 5110.

https://doi.org/10.1182/blood.V108.11.5110.5110

Published: 2006

Journal Articles

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Ralf Angermund, W. Knauf, M. Freund, M. R. Nowrousian, H. Einsele, H. Goldschmidt, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer

Blood (2005) 106 (11): 5156.

https://doi.org/10.1182/blood.V106.11.5156.5156

Published: 2005

Journal Articles

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey.

Mathias R.F. Freund, W. Knauf, H. Goldschmidt, H. Einsele, M. R. Nowrousian, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer, R. Angermund

Blood (2005) 106 (11): 5158.

https://doi.org/10.1182/blood.V106.11.5158.5158

Published: 2005

Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 366.

https://doi.org/10.1182/blood.V106.11.366.366

Published: 2005

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry.

Naeem Tahir, MD, Jerome H. Goldschmidt, MD, Eva Culakova, PHD, Marek S. Poniewierski, MD, MS, Debra A. Wolff, MS, PCNP, David C. Dale, MD, Jeffrey Crawford, MD, Gary H. Lyman, MD, MPH

Blood (2004) 104 (11): 3131.

https://doi.org/10.1182/blood.V104.11.3131.3131

Published: 2004

Journal Articles

Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

David C. Dale, MD, Jerome H. Goldschmidt, MD, Jeffrey Crawford, MD, Gary H. Lyman, MD, MPH, for the ANC Study Group

Blood (2004) 104 (11): 3314.

https://doi.org/10.1182/blood.V104.11.3314.3314

Published: 2004

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

Journal Articles

Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway

Duonan Yu, David Allman, Michael H. Goldschmidt, Michael L. Atchison, John G. Monroe, Andrei Thomas-Tikhonenko

Blood (2003) 101 (5): 1950–1955.

https://doi.org/10.1182/blood-2002-06-1797

Published: 2003

Journal Articles

Absence of a Correlation Between Kaposi’s Sarcoma–Associated Herpesvirus (KSHV/HHV-8) and Multiple Myeloma

G. Schönrich, M. Raftery, P. Schnitzler, U. Rohr, H. Goldschmidt

Blood (1998) 92 (9): 3474–3475.

https://doi.org/10.1182/blood.V92.9.3474

Published: 1998

Journal Articles

Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support

R Haas, B Witt, R Mohle, H Goldschmidt, S Hohaus, S Freuhauf, M Wannenmacher, W Hunstein

Blood (1995) 85 (12): 3754–3761.

https://doi.org/10.1182/blood.V85.12.3754.bloodjournal85123754

Published: 1995

Journal Articles

Blood-derived autografts collected during granulocyte colony- stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells

R Haas, R Mohle, M Pforsich, S Fruehauf, B Witt, H Goldschmidt, W Hunstein

Blood (1995) 85 (7): 1936–1943.

https://doi.org/10.1182/blood.V85.7.1936.bloodjournal8571936

Published: 1995

Journal Articles

Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma

R Haas, R Mohle, S Fruhauf, H Goldschmidt, B Witt, M Flentje, M Wannenmacher, W Hunstein

Blood (1994) 83 (12): 3787–3794.

https://doi.org/10.1182/blood.V83.12.3787.3787

Published: 1994

NARROW

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study

Gene Expression Profiles for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients Included in a Prospective, Multicenter, Phase 3 Trial.

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry.

Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway

Absence of a Correlation Between Kaposi’s Sarcoma–Associated Herpesvirus (KSHV/HHV-8) and Multiple Myeloma

Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support

Blood-derived autografts collected during granulocyte colony- stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells

Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only